関連情報 : PD-1 - バイオマーケットjp

「PD-1」に関連した情報

バイオ掲示板更新情報

バイオ掲示板更新情報 Former President Jimmy Carter, 91, Claims to Be Cancer-Free After Treatment for Metastatic Melanoma; Merck’s New Immunotherapy Drug KEYTRUDA Given Major Credit for Good Initial Result
... s by increasing the ability of the body’s immune system to fight advanced melanoma. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, and may affect both tumor cells and healthy cells. KEYTRUDA is the first anti-PD-1 (an ...
バイオ掲示板更新情報 Yet Another CRISPR/Cas9 Advance; UCSF & UC-Berkeley Scientists Modify Approach to Edit T-Cells to Disable CXCR4 Receptor for HIV and Also Manage to Knock Out PD-1 Protein That Inhibits T-Cell Attack on Cancers
... ed CXCR4, which can be exploited by HIV when the virus infects T cells and causes AIDS. The group also successfully shut down PD-1, a protein that has attracted intense interest in the burgeoning field of cancer immunotherapy, as scientists have shown ...
バイオ掲示板更新情報 PD-1 Pathway Does Not Cause T-Cell Exhaustion, Scientists Show
... ell exhaustion,” becoming less effective and losing their ability to attack and destroy the invaders of the body. While the PD-1 protein (programmed cell death protein 1) pathway has long been implicated as a primary player in T cell exhaustion, a m ...
バイオ掲示板更新情報 Merck Phase III Trial of Anti-PD-1 Drug (Keytruda) Meets Co-Primary Endpoints As First-Line Treatment for Advanced Melanoma and Trial Will Be Stopped Early; Keytruda Found Superior to Ipilimumab
... KEYTRUDA in this trial was similar to the safety profile previously reported in advanced melanoma. KEYTRUDA is the first anti-PD-1 therapy to demonstrate a survival advantage compared to the standard of care for the first-line treatment of advanced me ...
バイオ掲示板更新情報 FDA Expands Approval of BMS Opdivo to Include Lung Cancer; Previously Approved for Unresectable or Non-Responsive Metastatic Melanoma
... ncer patients, occurring when cancer forms in the cells of the lung. Opdivo works by inhibiting the cellular pathway known as PD-1 protein on cells that blocks the body’s immune system from attacking cancerous cells. Opdivo is intended for patients ...

すべて表示
運営会社:バイオアソシエイツ株式会社

バイオマーケットjpは、ライフサイエンス研究者・バイオビジネス関係者のための会員制サイトです。

ユーザー登録すると...

コンテンツの全文表示・コメント投稿・各種お申し込み・ダウンロード等、

様々なユーザー専用機能をご利用いただくことができます。

 

ユーザー登録は1分で完了

ユーザー登録は無料

運営者:バイオアソシエイツ株式会社

登録ユーザー数
2961人
2018年04月21日 現在
43 人のユーザが現在オンラインです。 (2 人のユーザが 関連情報 を参照しています。)
登録ユーザ: 0 ゲスト: 43
アクセスカウンター
DATEVisits/PVs
2018/04/21:284/1375
2018/04/20:833/14827

 

クリエイティブ・コモンズ・ライセンス
バイオマーケットjpのコンテンツは クリエイティブ・コモンズ 表示 - 非営利 - 改変禁止 4.0 国際 ライセンスの下に提供されています。引用される場合は出典元リンクの記載をお願いします。